Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Blood (2024) 144 (Supplement 1): 2187.

https://doi.org/10.1182/blood-2024-206919

Published: 2024

Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1504.3.

https://doi.org/10.1182/blood-2024-205101

Published: 2024

Journal Articles

Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Tingting Zhang, Li Liu, Xiaohui Zheng, Biao Shen, Ming Gong, Xin Liu, Gang Li, Ying Zhang, Wenbin Cao, Chen Liang, Aiming Pang, Yi He, Donglin Yang, Sizhou Feng, Mingzhe Han, Erlie Jiang

Blood (2024) 144 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2024-209406

Published: 2024

Journal Articles

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Fengkui Zhang, Li Zhang, Miao Chen, Hongyan Tong, Xiaoni Li, Wei Wang, Li Liu, Geoffrey Ross

Blood (2024) 144 (Supplement 1): 2701.

https://doi.org/10.1182/blood-2024-210973

Published: 2024

Journal Articles

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Mark J. Levis, Harry Erba, Pau Montesinos, Elzbieta Patkowska, Jorge E. Cortes, Herve Dombret, Alexander E. Perl, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Li Liu, Yasser M. Mostafa Kamel, Karima Imadalou, Abderrahmane Laadem, Mikkael A. Sekeres, Kristy Burns

Blood (2024) 144 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2024-207305

Published: 2024

Journal Articles

HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Han Gong, Bin Hu, Wenwen Xu, Pan Wang, Maohua Li, Ling Nie, Huifang Zhang, Li Liu, Yue Sheng, Long Liang, Xu Han, Mohandas Narla, Jing Liu

Blood (2024) 144 (Supplement 1): 3845.

https://doi.org/10.1182/blood-2024-207540

Published: 2024

Journal Articles

Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3 -ITD-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML)

Jaime E. Connolly Rohrbach, Edward Waldron, Li Liu, Shawn Rivera, Sridevi Kayyur Subramanya, Violet Abraham, Alexander E. Perl, Mark J. Levis

Blood (2024) 144 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2024-201727

Published: 2024

Journal Articles

Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Zhu Li, Yaling Zheng, Huanyu Wang, Chao Zhang, Li Liu, Lulu Lv, Li Zhou

Blood (2024) 144 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2024-199874

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Jia Li Liu, Nushin Sadeghi, Owen Luo, Jonathan How, John M. Storring, Gizelle Popradi

Blood (2024) 144 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2024-198536

Published: 2024

Journal Articles

Development of a Novel Allogeneic Super -Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors

Hanlu Wang, Li Liu, Chao Zhang, Junxiao Gao, Lulu Lv, Li Zhou

Blood (2024) 144 (Supplement 1): 2058.

https://doi.org/10.1182/blood-2024-201322

Published: 2024

Journal Articles

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Blood (2024) 144 (Supplement 1): 848.

https://doi.org/10.1182/blood-2024-203303

Published: 2024

Journal Articles

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Jaime E Rohrbach, Ken C N Chang, Maha Karnoub, Li Liu, Yasser Mostafa Kamel, Shirin Khambata-Ford, Shawn Rivera, Jelveh Lameh, Ekaterina Rudenko, Jordan Thornes, Sarah Todt, Jason Gerhold, Ying Huang, Jeffrey E Miller, Alexander Perl, Mark J. Levis, Kazumi Ito

Blood (2023) 142 (Supplement 1): 4260.

https://doi.org/10.1182/blood-2023-186658

Published: 2023

Journal Articles

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Pau Montesinos, Alexander Perl, Mikkael A. Sekeres, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Richard F Schlenk, Harry P. Erba, Hervé Dombret

Blood (2023) 142 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2023-187286

Published: 2023

Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Blood (2023) 142 (Supplement 1): 832.

https://doi.org/10.1182/blood-2023-186785

Published: 2023

Journal Articles

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Xiaoyu Zhang, Shulian Chen, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zepin Zhou, Fang Zhou, Rui Xi, Li Liu, Wei Yang, Xi Zhang, Qifa Liu, Erlie Jiang

Blood (2023) 142 (Supplement 1): 474.

https://doi.org/10.1182/blood-2023-184477

Published: 2023

Journal Articles

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

Blood (2023) 142 (Supplement 1): 2946.

https://doi.org/10.1182/blood-2023-184433

Published: 2023

Journal Articles

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Blood (2023) 142 (Supplement 1): 4951.

https://doi.org/10.1182/blood-2023-184407

Published: 2023

Journal Articles

Upfront Allogeneic Hematopoietic Stem Cell Transplantation Can Provide Survival Benefit Versus Hypomethylating Agent in Myelodysplastic Syndrome with Increased Blasts I (MDS-IB I)

Runzhi Ma, Sisi Zhen, Li Liu, Jieru Wang, Erlie Jiang, Sizhou Feng

Blood (2023) 142 (Supplement 1): 7094.

https://doi.org/10.1182/blood-2023-190923

Published: 2023

Journal Articles

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Harry P. Erba, Herve Dombret, Alexander Perl, Tsvetomir Mitov, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Youngsook Choi, Mark J. Levis, Richard F Schlenk

Blood (2023) 142 (Supplement 1): 972.

https://doi.org/10.1182/blood-2023-186206

Published: 2023

Journal Articles

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia

Xu Beilei, Chao Zhang, Junxiao Gao, Zhu Li, Shengzhen Ding, Li Liu, Hang Zhang, Lulu Lyu, Li Zhou

Blood (2023) 142 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2023-173608

Published: 2023

NARROW

Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Quantum-First: Deep-Dive Analysis of FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Detection Methods Utilized for Enrollment and Longitudinal MRD Detection in Newly Diagnosed (nd) Patients (pts) with FLT3 -ITD-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML)

Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases

Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience

Development of a Novel Allogeneic Super -Γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Quantum-First (Q-F): Clinical Bridging Study for FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Companion Diagnostic Development

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Recommendations on Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Combination of All- Trans Retinoic Acid and Arsenic Trioxide

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Upfront Allogeneic Hematopoietic Stem Cell Transplantation Can Provide Survival Benefit Versus Hypomethylating Agent in Myelodysplastic Syndrome with Increased Blasts I (MDS-IB I)

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only